In the latest sign that the major biopharma players are eagerly joining the big tech rush on the gene therapy market, Pfizer has snagged an option to buy a Paris-based biotech with a lead program a rare liver disease.
The pharma giant is paying $51 million to play, setting aside a stack of $636 million in milestone money if it chooses to go ahead with the buyout of Vivet Therapeutics on a near-term basis.